Parker Hughes Institute scientists develop 24 new drugs containing metal
Vanadium effective in fighting cancer cells
May 3, 2000, Saint Paul, Minn. ( In a systematic effort to develop effective drugs with a broad spectrum and potent anti-cancer activity, researchers at the St. Paul, Minn.-based Parker Hughes Institute have developed 24 new drugs containing the metal vanadium. The results of this research are published in this month¹s issue of Clinical Cancer Research, the official scientific journal of the American Association of Cancer Research.
These novel drugs were effective against 14 of 14 different cancer cell lines as well as cancer cells taken directly from patients. Targeted cancer cells included those of breast cancer, prostate cancer, testicular cancer, ovarian cancer, colon cancer, brain tumors, leukemia and lymphoma. These new anti-cancer drugs work by causing the cancer cells to commit suicide (or apoptosis) within 4 to 24 hours.
These drugs are now being tested in animal safety studies to identify those that have the best therapeutic index.
References Narla RK, Dong Y, D¹Cruz OJ, Navara C, Uckun FM. Bis (4,7-dimethyl-1, 10-phenanthroline) sulfatooxovanadium as a novel apoptosis-inducing anticancer agent. Clinical Cancer Research, 6:1546-56, 2000.
Ghosh P, D¹Cruz OJ, Narla RK, Uckun FM. Apoptosis-inducing vanadocene compounds against human testicular cancer. Clinical Cancer Research, 6:1536-45, 2000.
The Parker Hughes Institute www.hughesinstitute.org, located in Roseville, Minnesota, is a non-profit research organization dedicated to combating cancer, AIDS, and diseases of the immune system.